• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in bioscience: a journal and virtual library >New genomic landscapes and therapeutic targets for biliary tract cancers
【24h】

New genomic landscapes and therapeutic targets for biliary tract cancers

机译：胆道癌症的新基因组景观和治疗靶标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Biliary tract cancers (BTCs) are a heterogeneous group of neoplasms characterized by a dismal prognosis. At variance with most solid tumors, no effective molecular targeted agent has been currently approved for BTCs treatment and their molecular landscape has only been recently investigated. Comprehensive mutational profiling studies identified IDH1/2 and BAP1 as characteristic of intrahepatic cholangiocarcinomas, while extrahepatic cholangiocarcinomas and gallbladder carcinomas were characterized by frequent KRAS and TP53 alterations. Moreover, targeted next-generation sequencing has uncovered alterations in several key cellular pathways. BTC-specific alterations include disorders of major regulators of cell cycle and chromatin remodeling processes, as well as deregulation of the mTOR-, TGF- beta/Smad- and receptor tyrosine kinases signaling. The next step will be the correlation of these findings with clinical trials to identify predictive biomarkers for the development of personalized therapies. This will permit early access for BTC patients to innovative drugs.
机译：胆道癌症（BTC）是一种异质的肿瘤，其特征是令人沮丧的预后。在含有大多数实体瘤的方差下，目前没有有效的分子靶向剂用于BTCS治疗，并且它们的分子景观仅被研究。综合突变分析研究鉴定了IDH1 / 2和BAP1作为肝内胆管癌的特征，而额外的胆管癌和胆囊癌的特征是通过频繁的KRAS和TP53改变。此外，靶向的下一代测序在几种关键细胞途径中未被覆盖的改变。特异性改变包括细胞周期和染色质重塑过程的主要调节剂的障碍，以及MTOR - ，TGF-β/ Smad-和受体酪氨酸激酶信号传导的放松管制。下一步将是这些发现与临床试验的相关性，以确定用于开发个性化疗法的预测生物标志物。这将允许早期获得BTC患者的创新药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号